Clinical Trials · NCT01907854
Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin
- Phase
- Phase 4
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 407
- Start date
- Dec 2013
- Locations
- 106 sites, 7 countries
- Primary endpoint
- Change in HbA1c (Glycosylated Haemoglobin)